Author
A. N. Jones
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2020-2024 · peak 2/yrCo-Author Collaboration Network
10 top collaborators · 28 mutual co-author links6 papers
Recent·Most cited
Cooperativity in RNA chemical probing experiments modulates RNA 2D structure
E. B. Arnold, D. D. Cohn, E. M. Bose, G. Wolfe, A. N. Jones
This study shows that chemical probe concentration and size affect RNA structure and reactivity, leading to different 2D structure predictions.
bioRxiv · Dec 6, 2023Biochemistry
Despite the odds: formation of the SARS-CoV-2 methylation complex.
A. Matsuda, J. Plewka, Y. Chykunova, A. N. Jones, M. Pachota, M. Rawski, A. Mourao, A. Karim, L. Kresik, K. Lis, I. Minia, K. Hartman, R. Sonani, G. Dubin, M. Sattler, , A. Czarna
This study demonstrates that SARS-CoV-2 proteins nsp14, nsp10, and nsp16 form a heterotrimer complex, which modulates nsp14's exonuclease activity and protects viral RNA.
bioRxiv · Jan 25, 2022Microbiology
Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants
K. E. Zarn, S. A. Jaramillo, A. R. Zapata, N. E. Stone, A. N. Jones, H. E. Nunnally, E. W. Settles, K. Ng, P. S. Keim, S. Knudsen, P. M. Nuijten, A. S. Tijsma, C. T. French
This study shows that stenoparib inhibits SARS-CoV-2 variants in vitro, with EC50 values ranging from 4.1 to 24.1 M, and combination with remdesivir enhances antiviral effects.
bioRxiv · Nov 3, 2021Microbiology
Modulation of pre-mRNA structure by hnRNP proteins regulates alternative splicing of MALT1
A. N. Jones, C. Grass, I. Meininger, A. Geerlof, M. Klostermann, K. Zarnack, D. Krappmann, M. Sattler
The paper shows hnRNP proteins modulate MALT1 pre-mRNA structure to regulate alternative splicing of exon7 by competing for RNA stem-loop binding.
bioRxiv · Oct 12, 2021Biochemistry
Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 human coronavirus in vitro.
N. E. Stone, S. A. Jaramillo, A. N. Jones, A. J. Vazquez, M. Martz, L. M. Versluis, M. O. Raniere, H. E. Nunnally, K. E. Zarn, R. Nottingham, J. W. Sahl, D. M. Wagner, S. Knudsen, E. W. Settles, P. S. Keim, C. T. French
This paper evaluates stenoparib, a PARP inhibitor, for antiviral activity against SARS-CoV-2 and other coronaviruses in vitro, showing dose-dependent suppression and potential synergy with remdesivir.
bioRxiv · Nov 12, 2020 · PreprintMicrobiology